Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vaccines are among the most successful and cost-effective public health tools for preventing infectious diseases and death. Virus-like particles (VLPs) have made impressive progress in the field of vaccinology over the last three decades so that several VLP-based vaccines are commercially available and generating great public health impact, for example, the hepatitis B virus and the human papillomavirus (HPV) vaccines or in advanced clinical trials such as the RTS,S and R21 VLP malaria vaccines. We have growing in-house experience in Oxford of the use of a wide range of VLPs to target malaria and other diseases by vaccination. As VLPs lack genetic material, they have no replication capacity and are considered very safe. Additionally, VLP-based vaccines have significant ability to induce both innate and adaptive immune responses as well as being safe templates with favorable low-cost and large-scale manufacturing available.

Original publication

DOI

10.1016/B978-0-323-91146-7.00007-X

Type

Chapter

Book title

Vaccinology and Methods in Vaccine Research

Publication Date

01/01/2022

Pages

163 - 176